JP2023546536A5 - - Google Patents
Info
- Publication number
- JP2023546536A5 JP2023546536A5 JP2023547328A JP2023547328A JP2023546536A5 JP 2023546536 A5 JP2023546536 A5 JP 2023546536A5 JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023546536 A5 JP2023546536 A5 JP 2023546536A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical composition
- dose
- fibrosis
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026084780A JP2026124900A (ja) | 2020-10-13 | 2026-05-20 | 線維症を処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091128P | 2020-10-13 | 2020-10-13 | |
| US63/091,128 | 2020-10-13 | ||
| PCT/US2021/054713 WO2022081661A1 (en) | 2020-10-13 | 2021-10-13 | Methods of treating fibrosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026084780A Division JP2026124900A (ja) | 2020-10-13 | 2026-05-20 | 線維症を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023546536A JP2023546536A (ja) | 2023-11-02 |
| JP2023546536A5 true JP2023546536A5 (cg-RX-API-DMAC7.html) | 2024-11-14 |
| JP7868066B2 JP7868066B2 (ja) | 2026-06-01 |
Family
ID=81209448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547328A Active JP7868066B2 (ja) | 2020-10-13 | 2021-10-13 | 線維症を処置する方法 |
| JP2026084780A Pending JP2026124900A (ja) | 2020-10-13 | 2026-05-20 | 線維症を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026084780A Pending JP2026124900A (ja) | 2020-10-13 | 2026-05-20 | 線維症を処置する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11628167B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4229828A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7868066B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230107568A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116349204A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021360767A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198661A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022081661A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12605377B2 (en) | 2020-10-13 | 2026-04-21 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| JP7868066B2 (ja) | 2020-10-13 | 2026-06-01 | エンデバー バイオメディシンズ, インコーポレイテッド | 線維症を処置する方法 |
| CN120916760A (zh) * | 2023-02-28 | 2025-11-07 | 奋进生物医药公司 | 治疗纤维化的方法 |
| US12447148B2 (en) | 2024-03-05 | 2025-10-21 | Endeavor Biomedicines, Inc. | Methods of improving lung function |
| WO2025189041A1 (en) * | 2024-03-07 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025242197A1 (zh) * | 2024-05-24 | 2025-11-27 | 成都思倍博医药科技有限公司 | 氘代的Hedgehog通路SMO受体抑制剂 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148482B (cg-RX-API-DMAC7.html) | 1977-06-03 | 1981-03-07 | Pfizer | |
| AU717744B2 (en) | 1996-01-15 | 2000-03-30 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
| JP5067986B2 (ja) | 1998-04-09 | 2012-11-07 | ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン | ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用 |
| GB0013674D0 (en) | 1999-06-08 | 2000-07-26 | Lorantis Ltd | Therapeutic use |
| AU2003231032B2 (en) | 2002-04-22 | 2008-07-10 | Johns Hopkins University School Of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| WO2005033288A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
| WO2005080378A1 (ja) | 2004-02-24 | 2005-09-01 | Mitsubishi Pharma Corporation | 縮合ピリダジン誘導体 |
| EP1745039A4 (en) | 2004-05-08 | 2009-07-22 | Neurogen Corp | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES |
| WO2006028958A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| EP1900731A1 (de) | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| US8536168B2 (en) | 2007-03-15 | 2013-09-17 | Novartis Ag | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway |
| US8153633B2 (en) | 2007-06-25 | 2012-04-10 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| AU2008300019A1 (en) | 2007-09-07 | 2009-03-19 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
| CN102066353B (zh) | 2008-04-29 | 2013-12-11 | 伊莱利利公司 | 二取代的酞嗪Hedgehog通路拮抗剂 |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| CA2732101C (en) | 2008-08-04 | 2013-09-17 | Amgen Inc. | Aurora kinase modulators and methods of use |
| ES2418479T3 (es) | 2008-11-03 | 2013-08-14 | Eli Lilly And Company | Antagonistas de la ruta erizo de ftalazinas disustituidas |
| MX2011005177A (es) | 2008-11-17 | 2011-05-30 | Lilly Co Eli | Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas. |
| JP5518088B2 (ja) | 2008-11-17 | 2014-06-11 | イーライ リリー アンド カンパニー | 四置換ピリダジンヘッジホッグ経路アンタゴニスト |
| AR077014A1 (es) * | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
| WO2011088404A1 (en) | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
| GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| US9970935B2 (en) * | 2014-02-06 | 2018-05-15 | The Brigham And Women's Hospital, Inc. | Uses of GLI1 in detecting tissue fibrosis |
| GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
| EP3383912A4 (en) | 2015-11-30 | 2019-11-06 | Ignyta, Inc. | TOPICAL FORMULATIONS |
| US20190255042A1 (en) * | 2016-11-04 | 2019-08-22 | Impact Therapeutics, Inc | Application of hedgehog pathway inhibitor in treating fibrosis diseases |
| US11154541B2 (en) | 2018-06-29 | 2021-10-26 | The Trustees Of Indiana University | Methods for treating aortic valve stenosis with a hedgehog pathway inhibitor |
| CN112449602A (zh) * | 2018-07-19 | 2021-03-05 | 瓦里安医疗系统公司 | 超高剂量率辐射和治疗剂的使用方法 |
| JP7868066B2 (ja) | 2020-10-13 | 2026-06-01 | エンデバー バイオメディシンズ, インコーポレイテッド | 線維症を処置する方法 |
| US12605377B2 (en) | 2020-10-13 | 2026-04-21 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| CN120916760A (zh) | 2023-02-28 | 2025-11-07 | 奋进生物医药公司 | 治疗纤维化的方法 |
-
2021
- 2021-10-13 JP JP2023547328A patent/JP7868066B2/ja active Active
- 2021-10-13 CN CN202180069900.XA patent/CN116349204A/zh active Pending
- 2021-10-13 KR KR1020237015750A patent/KR20230107568A/ko active Pending
- 2021-10-13 WO PCT/US2021/054713 patent/WO2022081661A1/en not_active Ceased
- 2021-10-13 AU AU2021360767A patent/AU2021360767A1/en active Pending
- 2021-10-13 EP EP21880965.5A patent/EP4229828A4/en active Pending
- 2021-10-13 CA CA3198661A patent/CA3198661A1/en active Pending
-
2022
- 2022-05-03 US US17/735,798 patent/US11628167B2/en active Active
-
2023
- 2023-02-28 US US18/115,593 patent/US12295954B2/en active Active
-
2024
- 2024-06-26 US US18/755,445 patent/US12213974B2/en active Active
-
2025
- 2025-04-11 US US19/177,041 patent/US20250235452A1/en active Pending
-
2026
- 2026-05-20 JP JP2026084780A patent/JP2026124900A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法(ベムラフェニブ及びmdm2阻害剤) | |
| KR102634247B1 (ko) | 다발성 골수종을 치료하기 위한 약물 병용물 | |
| KR20140022048A (ko) | 선택된 환자에서의 피르페니돈 및 항-섬유성 치료제 | |
| JP2019515884A5 (cg-RX-API-DMAC7.html) | ||
| JP6091593B2 (ja) | 慢性閉塞性肺疾患の急性増悪の治療におけるピラゾール誘導体の使用 | |
| EA020193B1 (ru) | Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh) | |
| JP2004521134A5 (cg-RX-API-DMAC7.html) | ||
| EP1358177B1 (en) | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | |
| JP6145946B2 (ja) | 併用als療法 | |
| JP2019520344A5 (cg-RX-API-DMAC7.html) | ||
| JP2019533660A5 (cg-RX-API-DMAC7.html) | ||
| JP2026510290A (ja) | 線維症を処置する方法 | |
| JP2022518788A (ja) | オピオイド鎮痛耐性を治療するためのmGluR5アンタゴニストの使用 | |
| Li et al. | A comparative study of esketamine-propofol and sufentanil-propofol for analgesia and sedation during breast minimally invasive rotary resection with local anesthesia: a randomized double-blind clinical trial | |
| JP2023528896A5 (cg-RX-API-DMAC7.html) | ||
| JP2013536206A5 (cg-RX-API-DMAC7.html) | ||
| JP2019531286A5 (cg-RX-API-DMAC7.html) | ||
| JP2020050624A (ja) | 線維症治療用医薬組成物 | |
| JP2021519285A (ja) | ダブラフェニブ、トラメチニブ及びerk阻害剤を含む医薬品の三重の組合せ | |
| JP2009510142A (ja) | 急性および慢性肺障害の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用 | |
| JP5862897B2 (ja) | 腎機能障害の予防又は治療に用いる医薬 | |
| CN119837862A (zh) | 玛沃谷兰在减少酒精使用或在预防复用酒精中的用途 | |
| JP2003513888A (ja) | 神経疾患治療用医薬品 | |
| JP2024523558A5 (cg-RX-API-DMAC7.html) | ||
| US20240207274A1 (en) | Larotrectinib and moderate CYP3A4 inducer |